1. Show article details.

    ZELTIQ(R) Aesthetics Showcasing New CoolSmooth PRO(TM) Applicator at American Academy of Dermatology Annual Meeting

    Market Wire – 5:00 PM ET 03/19/2015

    03/19/15 -- ZELTIQ® Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it is showcasing its CoolSmooth PRO™ applicator, a second generation surface applicator featuring non-vacuum based cooling to treat non-pinchable fat bulges such as the outer thigh area, at the...

  2. Show article details.

    ZELTIQ Announces Fourth Quarter and Full Year 2014 Financial Results

    Market Wire – 4:05 PM ET 03/03/2015

    03/03/15 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the fourth quarter and full year 2014.

  3. Show article details.

    ZELTIQ to Present at Investor Conferences in March 2015

    Market Wire – 4:05 PM ET 02/27/2015

    02/27/15 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Patrick F. Williams, Senior Vice President and Chief Financial Officer, is scheduled to present in two investor conferences in March 2015.

  4. Show article details.

    ZELTIQ Announces Conference Call and Webcast of Fourth Quarter and Full Year 2014 Financial Results to Be Held on March 3, 2015

    Market Wire – 4:05 PM ET 02/10/2015

    02/10/15 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its fourth quarter and full year 2014 financial results on Tuesday, March 3, 2015 after the market close.

  5. Show article details.

    ZELTIQ to Present at Investor Conferences in February 2015

    Market Wire – 4:05 PM ET 02/02/2015

    02/02/15 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to participate in two investor conferences in February 2015.

  6. Show article details.

    ZELTIQ® Receives FDA Clearance to Perform CoolSculpting® Procedure at Lower Temperatures for Shorter Treatment Times

    Business Wire – 8:30 AM ET 01/29/2015

    ZELTIQ® Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that it has received Food and Drug Administration clearance to perform the CoolSculpting® procedure at lower temperatures, which will enable shorter treatment times.

  7. Show article details.

    CoolSculpting(R) Procedure Named "Best Fat-Reducing Treatment" by NewBeauty(R) Magazine

    Market Wire – 8:00 AM ET 01/27/2015

    01/27/15 -- The CoolSculpting® procedure, a non-invasive procedure that uses cooling technology to noticeably eliminate fat without surgery was awarded "Best Fat-Reducing Treatment" by NewBeauty® magazine, the definitive authority on all things beauty.

  8. Show article details.

    New Year, New You, New Findings -- New Survey Reveals What Women Expect to Gain by Keeping New Year's Resolution to "Lose the Fat"

    Market Wire – 8:00 AM ET 01/21/2015

    01/21/15 -- There is so much to gain from losing fat, it is no wonder that more than 1 in 2 women put "losing fat" on their New Year's resolution list this year. Three-quarters of the women surveyed agreed that when they look their best, they feel their best.

  9. Show article details.

    Technical Commentary on Health Care Equipment Stocks - Hologic, St. Jude Medical, Covidien, Wright Medical, and Zeltiq Aesthetics

    PR Newswire – 9:00 AM ET 01/14/2015

    LONDON, January 14, 2015 Investor-Edge has initiated coverage on the following equities: Hologic Inc. (HOLX), St Jude Medical Inc. (STJ), Covidien PLC (COV), Wright Medical Group Inc. (WMGI), and Zeltiq Aesthetics Inc. (ZLTQ). Free research on these five companies can be accessed at: http://investor-edge.com/register.

  10. Show article details.

    ZELTIQ to Present at J.P. Morgan 33rd Annual Healthcare Conference

    Market Wire – 8:10 PM ET 01/13/2015

    01/13/15 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, CoolSculpting®, will present at the J.P. Morgan 33rd Annual Healthcare Conference tomorrow, Wednesday, January 14, 2015.

  11. Show article details.

    ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2014 Revenue

    Market Wire – 4:01 PM ET 01/13/2015

    01/13/15 -- ZELTIQ® ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, CoolSculpting®, announced today preliminary unaudited revenue for the fourth quarter and full year 2014.

  12. Show article details.

    ZELTIQ to Present at the J.P. Morgan 33rd Annual Healthcare Conference

    Market Wire – 8:30 AM ET 01/05/2015

    01/05/15 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at the Westin St. Francis Hotel in San Francisco.

  13. Show article details.

    ZELTIQ(R) Aesthetics Named Fastest Growing Medical Device Company in North America by Deloitte's 2014 Technology Fast 500(TM)

    Market Wire – 5:30 AM ET 11/13/2014

    11/13/14 -- ZELTIQ Aesthetics, Inc. (ZLTQ) today announced it is ranked number one in medical devices on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.

  14. Show article details.

    ZELTIQ Announces Third Quarter 2014 Financial Results

    Market Wire – 4:05 PM ET 10/28/2014

    10/28/14 -- ZELTIQ® ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the third quarter 2014.

  15. Show article details.

    ZELTIQ to Present at Investor Conferences in November 2014

    Market Wire – 4:05 PM ET 10/22/2014

    10/22/14 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to participate in various investor conferences in November 2014.

  16. Show article details.

    ZELTIQ(R) Aesthetics Showcasing Its CoolSculpting(R) Procedure at Plastic Surgery The Meeting 2014

    Market Wire – 7:51 PM ET 10/10/2014

    10/10/14 -- ZELTIQ Aesthetics, Inc. (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it is showcasing its CoolSculpting procedure at Plastic Surgery The Meeting in Chicago, October 10-14, 2014. WHAT: CoolSculpting Procedure and CoolSculpting Business Reviews.

  17. Show article details.

    ZELTIQ Announces Conference Call and Webcast of Third Quarter 2014 Financial Results to Be Held on October 28, 2014

    Market Wire – 4:05 PM ET 10/07/2014

    10/07/14 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its third quarter 2014 financial results on Tuesday, October 28, 2014 after the market close.

Page:

Today's and Upcoming Events

  • Apr
    28

    ZLTQ to announce Q1 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Mar
    3

    ZLTQ Earnings Conference Call at 4:30 PM Listen

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.